Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY: GKOS )

151.22 UNCHANGED
Streaming Delayed Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
25 Stocks Moving in Wednesday's Pre-Market Session
Gainers Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 56.4% to $26.20 in pre-market trading on the heels of three new announcements from the company outlining strategic plans to... 
Via Benzinga
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
From Glaukos Corporation
Via Business Wire
Why Glaukos Shares Dipped Today
Glaukos (NYSE:GKOS) shares are trading lower after Wells Far... 
Via Benzinga
Glaukos plunges after CMS suggests slashing iStent reimbursement
William Blair downgraded Glaukos following the 
Via Talk Markets
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
From Glaukos Corporation
Via Business Wire
Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos
Glaukos Corp (NYSE:GKOS) has 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
From Glaukos Corporation
Via Business Wire
Glaukos Files Pre-Market Application For Intraocular Pressure Device
Glaukos Corp (NYSE: GKOS) has submitted a supplemental premarket approval (PMA) application to the FDA for its iStent infinite Trabecular Micro-Bypass System.... 
Via Benzinga
Exposures Product Safety
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
From Glaukos Corporation
Via Business Wire
Return on Capital Employed Overview: Glaukos
Pulled from Benzinga Pro data Glaukos (NYSE:GKOS) reported Q2 sales of $78.09 million. Earnings fell to a loss of $14.22 million, resulting in a 20.47% decrease from last quarter... 
Via Benzinga
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies
From Glaukos Corporation
Via Business Wire
Glaukos Guided Below Consensus After Q2 Earnings; Analysts Cut Price Target
Glaukos Corporation (NYSE:GKOS) 
Via Benzinga
Glaukos Corp (GKOS) Q2 2021 Earnings Call Transcript
GKOS earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Glaukos Corporation Announces Second Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Why Glaukos Stock Sank Today
An analyst downgraded the healthcare stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 26, 2021
Upgrades Tudor Pickering upgraded the previous rating for Precision Drilling Corp (NYSE: 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares surged 208% to settle at $10.04 on Tuesday as the company said it received FDA breakthrough device designation for the treatment... 
Via Benzinga
Exposures Product Safety
Wells Fargo Downgrades Glaukos To Sell On iStent Reimbursement Cuts
Wells Fargo analyst Lawrence Biegelsen downgraded Glaukos to Underweight from Equal Weight with a price target of $41, down from $100. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
Upgrades For Bank of Marin Bancorp (NASDAQ: 
Via Benzinga
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
From Glaukos Corporation
Via Business Wire
Mid-Afternoon Market Update: Dow Gains 50 Points; Imara Shares Plunge
Toward the end of trading Wednesday, the Dow traded up 0.15% to 34,942.77 while the NASDAQ rose 0.07% to 14,687.21. The S&P also rose, gaining 0.26% to 4,380.58. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
55 Biggest Movers From Yesterday
Gainers SGOCO Group, Ltd. (NASDAQ: SGOC) shares gained 37.6% to settle at $13.20 on Wednesday. SGOCO Group regained compliance with Nasdaq's listing standards on July 12 by... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers AcelRx Pharmaceuticals (NASDAQ:ACRX 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.